Belimumab add on improves renal response in lupus nephritis patients: NEJM

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-11-02 11:00 GMT | Update On 2020-11-03 10:10 GMT

USA: The addition of belimumab to standard therapy improved renal outcomes in patients with lupus nephritis, according to a recent study in the New England Journal of Medicine.

Brad H. Rovin, Ohio State University, and colleagues aimed to determine the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide–azathioprine), in patients with active lupus nephritis.

For the purpose, the researchers conducted a phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 104-week trial at 107 sites in 21 countries. 448 patients were assigned to receive intravenous belimumab (at a dose of 10 mg per kilogram of body weight) -- belimumab group (n=224) or matching placebo (n=224), in addition to standard therapy.

The primary end point at week 104 was a primary efficacy renal response (a ratio of urinary protein to creatinine of ≤0.7, an estimated glomerular filtration rate [eGFR] that was no worse than 20% below the value before the renal flare (pre-flare value) or ≥60 ml per minute per 1.73 m2 of body-surface area, and no use of rescue therapy).

Key findings of the study include:

At week 104, significantly more patients in the belimumab group than in the placebo group had a primary efficacy renal response (43% vs. 32%; odds ratio, 1.6) and a complete renal response (30% vs. 20%; odds ratio, 1.7).
The risk of a renal-related event or death was lower among patients who received belimumab than among those who received placebo (hazard ratio, 0.51).
The safety profile of belimumab was consistent with that in previous trials.

"In this trial involving patients with active lupus nephritis, more patients who received belimumab plus standard therapy had a primary efficacy renal response than those who received standard therapy alone," concluded the authors.

"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis," is published in the New England Journal of Medicine.

DOI: https://www.nejm.org/doi/full/10.1056/NEJMoa2001180

Article Source : New England Journal of Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Belimumab add on improves renal response in lupus nephritis patients: NEJM

Similar News

Involuntary Leaks: Study Investigating Stress Urinary Incontinence During Pregnancy

UTIs Linked to Short-Term Increased Risk of Heart Attack and Stroke, reveals research

Two-Thirds of Indian Children With Lupus Develop Nephritis Early, Registry Finds

Patients undergoing dialysis before transplantation have increased diabetic retinopathy risk: Study

Stress Hyperglycemia Ratio Identified as Reliable Predictor of AKI in CKD Patients: Study

Higher BMI and Depression Linked to Greater Risk of Urinary Incontinence in Women: NHANES Study

Kidney Injury Significantly Increases Hypertension Risk, Study Finds

Prioritize Sustained decongestion over preserving kidney function in modest eGFR decline: Study